ClearNote Health presented updated validation data for its Avantect Pancreatic Cancer test at the American Association for Cancer Research annual meeting. The company reported that adding a glycan biomarker (CA19-9) to its 5-hydroxymethylcytosine (5hmC) measurements and cfDNA fragment size genotyping improved overall performance in a validation cohort. In that validation cohort of 1,445 high-risk patients (259 with cancer), the assay showed overall sensitivity of 82.6% with specificity at 97.5%. The company further reported sensitivity of 76.8% in early-stage disease and described stage I sensitivity variability across cohorts, alongside additional work in groups including patients with new-onset type 2 diabetes. ClearNote also said it is continuing studies for its multi-cancer early detection efforts, positioning the pancreatic program as an early proof point for broader liquid biopsy strategies.